INNOVIVA INC (INVA) Stock Price, Quote, News and Overview
NASDAQ:INVA - Nasdaq - US45781M1018 - Common Stock - Currency: USD
INVA Quote, Performance and Key Statistics
21.37
-0.16 (-0.74%)
The current stock price of INVA is 21.37 USD. In the past month the price increased by 17.03%. In the past year, price increased by 34.32%.
INVA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 58.77 | 766.35B | ||
| JNJ | JOHNSON & JOHNSON | 15.45 | 373.57B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 21.87 | 349.83B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 14.21 | 233.20B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 16.76 | 228.63B | ||
| MRK | MERCK & CO. INC. | 10.31 | 201.69B | ||
| PFE | PFIZER INC | 7.63 | 139.18B | ||
| SNY | SANOFI-ADR | 11.14 | 120.95B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 6.83 | 102.08B | ||
| GSK | GSK PLC-SPON ADR | 9.37 | 84.35B | ||
| ZTS | ZOETIS INC | 27.63 | 74.05B | ||
| HLN | HALEON PLC-ADR | 22.27 | 49.09B |
Related stock screener links
About INVA
Company Profile
Innoviva, Inc. is engaged in the development, commercialization, and financial management of biopharmaceuticals. The company is headquartered in Burlingame, California and currently employs 127 full-time employees. The company went IPO on 2004-10-05. The firm's royalty portfolio consists of respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR/BREO ELLIPTA (fluticasone furoate/vilanterol, FF/VI) and ANORO ELLIPTA (umeclidinium bromide/vilanterol, UMEC/VI). Under the Long-Acting Beta2 Agonist (LABA) Collaboration Agreement, the Company is entitled to receive royalties from GSK on sales of RELVAR/BREO, ELLIPTA. The firm's products include GIAPREZA (angiotensin II), approved to increase blood pressure in adults with septic or other distributive shock, and XERAVA (eravacycline) approved for the treatment of complicated intra-abdominal infections in adults. The third product, XACDURO (formerly known as sulbactam-durlobactam or SUL-DUR), is approved for the treatment of hospital-acquired and ventilator-associated pneumonias caused by Acinetobacter in adults. The development pipeline includes zoliflodacin, an investigational treatment for uncomplicated gonorrhea is in Phase III clinical trial.
Company Info
INNOVIVA INC
1350 Old Bayshore Highway, Suite 400
Burlingame CALIFORNIA 94010 US
CEO: Pavel Raifeld
Employees: 127
Phone: 16502389600
INNOVIVA INC / INVA FAQ
What is the stock price of INNOVIVA INC today?
The current stock price of INVA is 21.37 USD. The price decreased by -0.74% in the last trading session.
What is the ticker symbol for INNOVIVA INC stock?
The exchange symbol of INNOVIVA INC is INVA and it is listed on the Nasdaq exchange.
On which exchange is INVA stock listed?
INVA stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for INNOVIVA INC stock?
8 analysts have analysed INVA and the average price target is 56.1 USD. This implies a price increase of 162.52% is expected in the next year compared to the current price of 21.37. Check the INNOVIVA INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is INNOVIVA INC worth?
INNOVIVA INC (INVA) has a market capitalization of 1.34B USD. This makes INVA a Small Cap stock.
How many employees does INNOVIVA INC have?
INNOVIVA INC (INVA) currently has 127 employees.
What are the support and resistance levels for INNOVIVA INC (INVA) stock?
INNOVIVA INC (INVA) has a support level at 18.86. Check the full technical report for a detailed analysis of INVA support and resistance levels.
Is INNOVIVA INC (INVA) expected to grow?
The Revenue of INNOVIVA INC (INVA) is expected to grow by 3.16% in the next year. Check the estimates tab for more information on the INVA EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy INNOVIVA INC (INVA) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of INVA, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of INVA, evaluating the profitability, health, valuation and growth aspects
- INNOVIVA INC (INVA) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- INNOVIVA INC (INVA) Sales and EPS estimates to see what analysts future expectations are.
- INNOVIVA INC (INVA) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- INNOVIVA INC (INVA) Insider and Institutional Ownership to learn about the owners and their transactions.
- INNOVIVA INC (INVA) Stock Chart to make your own analysis
- INNOVIVA INC (INVA) Latest news and press-releases to stay up to date.
Does INNOVIVA INC (INVA) stock pay dividends?
INVA does not pay a dividend.
When does INNOVIVA INC (INVA) report earnings?
INNOVIVA INC (INVA) will report earnings on 2025-07-29.
What is the Price/Earnings (PE) ratio of INNOVIVA INC (INVA)?
INNOVIVA INC (INVA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.01).
What is the Short Interest ratio of INNOVIVA INC (INVA) stock?
The outstanding short interest for INNOVIVA INC (INVA) is 14% of its float. Check the ownership tab for more information on the INVA short interest.
INVA Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to INVA. When comparing the yearly performance of all stocks, INVA is one of the better performing stocks in the market, outperforming 89.2% of all stocks.
INVA Fundamental Analysis
ChartMill assigns a fundamental rating of 6 / 10 to INVA. While INVA has a great health rating, its profitability is only average at the moment.
INVA Financial Highlights
Over the last trailing twelve months INVA reported a non-GAAP Earnings per Share(EPS) of -1.01. The EPS decreased by -145.5% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -4.76% | ||
| ROE | -9.23% | ||
| Debt/Equity | 0.4 |
INVA Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 83% to INVA. The Buy consensus is the average rating of analysts ratings from 8 analysts.
For the next year, analysts expect an EPS growth of 259.68% and a revenue growth 3.16% for INVA